TY - JOUR
T1 - Unrelated donor marrow transplantation in children with severe aplastic anaemia using cyclophosphamide, anti-thymocyte globulin and total body irradiation
AU - Kojima, Seiji
AU - Inaba, Jun
AU - Yoshimi, Ayami
AU - Takahashi, Yoshiyuki
AU - Watanabe, Nobuhiro
AU - Kudo, Kazuko
AU - Horibe, Keizo
AU - Maeda, Naoko
AU - Kato, Koji
AU - Matsuyama, Takaharu
PY - 2001
Y1 - 2001
N2 - We report a favourable outcome in 15 patients with severe aplastic anaemia (SAA) who were <20 years of age and who underwent bone marrow transplantation (BMT) from a human leucocyte antigen (HLA)-matched unrelated donor. All patients were non-responders to intensive immunosuppressive therapy (IST) and were multiply transfused. The conditioning regimen consisted of cyclophosphamide (60 mg/kg/d, on d -4 and -3), anti-thymocyte globulin (2·5 mg/kg/d, on d -5 to -2) and total body irradiation (2·5 Gy×2/d, on d -2 and -1). Patients received cyclosporine and methotrexate for prophylaxis of graft-versus-host disease (GVHD), except for the last four who received tacrolimus instead of cyclosporine. Donor/recipient pairs were identical for HLA class I and II antigens by serological typing, but four pairs were found to have a mismatch at the HLA-A, -B or -DRB1 locus by high-resolution typing. All patients achieved rapid engraftment and are alive at 2-86 months after transplantation (median follow-up, 51 months). Moderate to severe acute GVHD occurred in 5 out of 15 patients (33%); only one patient developed extensive chronic GVHD. Considering our encouraging results, unrelated donor transplantation for SAA is recommended as a salvage therapy in non-responders to IST.
AB - We report a favourable outcome in 15 patients with severe aplastic anaemia (SAA) who were <20 years of age and who underwent bone marrow transplantation (BMT) from a human leucocyte antigen (HLA)-matched unrelated donor. All patients were non-responders to intensive immunosuppressive therapy (IST) and were multiply transfused. The conditioning regimen consisted of cyclophosphamide (60 mg/kg/d, on d -4 and -3), anti-thymocyte globulin (2·5 mg/kg/d, on d -5 to -2) and total body irradiation (2·5 Gy×2/d, on d -2 and -1). Patients received cyclosporine and methotrexate for prophylaxis of graft-versus-host disease (GVHD), except for the last four who received tacrolimus instead of cyclosporine. Donor/recipient pairs were identical for HLA class I and II antigens by serological typing, but four pairs were found to have a mismatch at the HLA-A, -B or -DRB1 locus by high-resolution typing. All patients achieved rapid engraftment and are alive at 2-86 months after transplantation (median follow-up, 51 months). Moderate to severe acute GVHD occurred in 5 out of 15 patients (33%); only one patient developed extensive chronic GVHD. Considering our encouraging results, unrelated donor transplantation for SAA is recommended as a salvage therapy in non-responders to IST.
UR - http://www.scopus.com/inward/record.url?scp=17944369592&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=17944369592&partnerID=8YFLogxK
U2 - 10.1046/j.1365-2141.2001.02992.x
DO - 10.1046/j.1365-2141.2001.02992.x
M3 - Article
C2 - 11553002
AN - SCOPUS:17944369592
SN - 0007-1048
VL - 114
SP - 706
EP - 711
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 3
ER -